SCMP Key Statistics, Chart & Performance
The current stock price of SCMP is 18 null. In the past month the price decreased by -0.28%. In the past year, price increased by 52.54%.
SCMP Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to SCMP. When comparing the yearly performance of all stocks, SCMP is one of the better performing stocks in the market, outperforming 95.42% of all stocks.
SCMP Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to SCMP. Both the profitability and the financial health of SCMP get a neutral evaluation. Nothing too spectacular is happening here.
SCMP Financial Highlights
Over the last trailing twelve months SCMP reported a non-GAAP Earnings per Share(EPS) of -3.3369. The EPS decreased by -1216.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -60.24% | ||
| ROA | -38.88% | ||
| ROE | -380.71% | ||
| Debt/Equity | 7.37 |
SCMP Forecast & Estimates
SCMP Ownership
About SCMP
Company Profile
Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products - AMITIZA, its lead product, and RESCULA - and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.
Company Info
Sucampo Pharmaceuticals
805 King Farm Boulevard Suite 550
Rockville MD 20850
CEO: Peter Greenleaf
Phone: 301-961-3400
Sucampo Pharmaceuticals / SCMP FAQ
Can you describe the business of Sucampo Pharmaceuticals?
Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products - AMITIZA, its lead product, and RESCULA - and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.
Can you provide the latest stock price for Sucampo Pharmaceuticals?
The current stock price of SCMP is 18 null.
Does Sucampo Pharmaceuticals pay dividends?
SCMP does not pay a dividend.
How is the ChartMill rating for Sucampo Pharmaceuticals?
SCMP has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Which stock exchange lists SCMP stock?
SCMP stock is listed on the Nasdaq exchange.